ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in ...